Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Current Liabilities (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Total Current Liabilities for 2 consecutive years, with $53.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 106.68% to $53.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.0 million through Dec 2025, up 106.68% year-over-year, with the annual reading at $53.0 million for FY2025, 106.68% up from the prior year.
  • Total Current Liabilities hit $53.0 million in Q4 2025 for Prelude Therapeutics, up from $18.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $53.0 million in Q4 2025 to a low of $17.6 million in Q1 2024.